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Abstract
Objectives: The neurobiological basis for autism remains poorly understood. However, research suggests that
environmentalfactors and neuroinflammation, as well as genetic factors, are contributors. This study aims to test the
role that might be played by heat shock protein (HSP)70, transforming growth factor (TGF)-β2, Caspase 7 and
interferon-γ (IFN-γ)in the pathophysiology of autism.
Materials and methods: HSP70, TGF-β2, Caspase 7 and INF-γ as biochemical parameters related to inflammation
were determined in plasma of 20 Saudi autistic male patients and compared to 19 age- and gender-matched
control samples.
Results: The obtained data recorded that Saudi autistic patients have remarkably higher plasma HSP70, TGF-β2,
Caspase 7 and INF-γ compared to age and gender-matched controls. INF-γ recorded the highest (67.8%) while
TGF-β recorded the lowest increase (49.04%). Receiver Operating Characteristics (ROC) analysis together with
predictiveness diagrams proved that the measured parameters recorded satisfactory levels of specificity and
sensitivity and all could be used as predictive biomarkers.
Conclusion: Alteration of the selected parameters confirm the role of neuroinflammation and apoptosis
mechanisms in the etiology of autism together with the possibility of the use of HSP70, TGF-β2, Caspase 7 and
INF-γ as predictive biomarkers that could be used to predict safety, efficacy of a specific suggested therapy or
natural supplements, thereby providing guidance in selecting it for patients or tailoring its dose.
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Introduction
Autism is a complex neurodevelopmental disorder of
early onset that is highly variable in its clinical presenta-
tion. Although the causes of autism in most patients re-
main unknown, several lines of research support the
view that susceptibility to autism is clearly attributed to
both genetic and environmental factors that influence
the development of abnormal cortical circuitry that
underlies autistic cognitive processes, social impairment
and other behaviors [1]. Additionally, recent evidence
points to inflammatory mechanisms contributing toaut-
ism. Vargas et al. [2] suggested neuroinflammatory pro-
cesses are present in the autistic brain by showing that
transforming growth factor (TGF-β1), interleukin (IL) 6
and IL10 are increased in the brain of autistic patients.
A number of studies have also shown that inflammatory
cytokines, including tumor necrosis factor (TNF) α,
interferon (IFN) γ, IL1, IL6, IL8 and IL12, are elevated in
blood mononuclear cells, serum, plasma and cerebro-
spinal fluid (CSF) of autistic subjects [2-8].
The role of extracellular 70 kDa heat shock protein 70
(HSP70) in central nervous system inflammation is
vastly understudied, despite evidence supporting its abil-
ity to drive a pro-inflammatory state [9]. Heat shock
proteins (HSPs) are induced in response to many injuries
including stroke, neurodegenerative disease, epilepsy and
trauma. The overexpression of HSP70 serves a protect-
ive role in several different models of nervous system in-
jury, but has also been linked to a deleterious role in
some diseases [10].
The transforming growth factor-β (TGF-β) superfamily
is a multifunctional family of cytokines that has a critical
role in the regulation of key events of development,
disease and tissue repair in the nervous system. Accu-
mulating evidence suggests that TGF-β has emerged as
a crucial regulator of nervous system physiology, al-
though it has been widely considered as an injury-
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related cytokine [11]. It is still unclear whether plasma
TGF-β levels could reflect its brain concentration since
it is shown that it can cross the disrupted but not the in-
tact blood–brain barrier (BBB) [12].
It is well known that activation of cysteinyl aspartate-
specific proteases (caspases) may underlie apoptotic cell
death in the brain. Caspase 3, 6 and 7 likely contribute
to such cell death in a stimulus- and cell type-specific
manner [13]. Recent studies proved the activation of cas-
pases 3, 7 and 12 in peripheral blood mononuclear cells
(PBMCs) from 15 autistic children compared to age-
matched normal healthy developing controls [14] In
addition, El-Ansary et al. [8] recorded an elevation of
Caspase 3 in plasma of Saudi autistic children compared
to control subjects.
In a study done by Li et al. [15], the immune activities
in the brain of autistic patients were significantly higher
compared to matched normal subjects. Proinflammatory
cytokines (TNF-α, IL-6), Th1 cytokine (IFN-γ) were the
most significantly increased.
Considering the protective and/or the deleterious ef-
fect of HSP70, the key role of TGF-β in brain develop-
ment [11], the possible role of caspase pathway, and the
suggested role of localized brain inflammation and auto-
immunity in the pathology of autism, it is of great inter-
est to measure these parameters in plasma of the Saudi
population compared to controls in an attempt to
understand and clarify their roles in the etiology of this
disorder.
Subjects and methods
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000).
All 20 autistic subjects enrolled in the study had written
informed consent provided by their parents and assented
to participate if developmentally able. Subjects for this
study were enrolled through the ART Center (Autism
Research and Treatment Center) clinic. The ART Center
clinic sample population consisted of children diagnosed
with Autism Spectrum Disorder (ASD). The diagnosis of
ASD was confirmed in all subjects using the Autism
Diagnostic Interview-Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS) and 3DI (De-
velopmental, dimensional diagnostic interview). The ages
of all autistic children ranged between 3 and 16 years
old. All were non-verbal males. Intelligence quotient
(IQ) for all autistic children was below 80. All were sim-
plex cases. All are negative for fragile × gene study. The
19 healthy control subjects were recruited from the
well-baby clinic at King Khaled University Hospital and
they were 3 to 16 years old. All participating subjects
were excluded from the investigation if they had dis-
morphic features, tuberous sclerosis, Angleman syn-
drome, or other serious neurological (for example,
seizures), psychiatric (for example, bipolar disorder) or
known medical conditions. All participants were
screened via parental interview for current and past
physical illness. Children with known endocrine, cardio-
vascular, pulmonary, liver, kidney or other medical dis-
ease were excluded from the study.
Ethics approval and consent
This work was ethically approved by the ethical commit-
tee of King Khalid Hospital, King Saud University (Ap-
proval number is 11/2890/IRB). A written consent was
obtained from the parents of each individual case,
according to the guidelines of the ethical committee.
Samples collection
After an overnight fast, 10 ml blood samples were col-
lected from both groups in test tubes containing heparin
as an anticoagulant. Centrifugation was done; plasma
was obtained and deep frozen (at −80°C) until analysis
time.
Chemicals and kits
All chemicals and kits used in this study were of analyt-
ical grade, a product of Sigma-Aldrich Corp, St Louis,
USA. Uscn LifeScience Inc, Wuhan, China; Quantikine,
R & D Systems, Inc, Minneapolis, USA and Thermo-
scientific (Rockford, IL, USA).
Biochemical assays
Assay of heat shock protein 70 (HSP70)
HSP70 was measured using an ELISA kit, product of
Uscn Life Science Inc., Wuhan, China, according to the
manufacturer’s instructions. The microtiter plate pro-
vided in this kit has been pre-coated with an antibody
specific for HSP70. Standards or samples are then added
to the appropriate microtiter plate wells with a biotin-
conjugated polyclonal antibody preparation specific for
HSP70. Next, avidin conjugated to horseradish peroxid-
ase (HRP) is added to each microplate well and incu-
bated for two hours at 37°C. Then, a 3,3', 5,5'
tetramethylbenzidine (TMB) substrate solution is added
to each well. Only those wells that contain HSP70,
biotin-conjugated antibody and enzyme-conjugated
avidin will exhibit a change in color. The enzyme-
substrate reaction is terminated by the addition of a sul-
furic acid solution and the color change is measured
spectrophotometrically at a wavelength of 450 nm± 10
nm. The concentration of HSP70 in the samples is then
determined by comparing the optical density of the sam-
ples to the standard curve. The minimum detectable
level of HSP70 detected is less than 0.045 ng/ml.
El-Ansary and Al-Ayadhi Journal of Neuroinflammation 2012, 9:265 Page 2 of 9
http://www.jneuroinflammation.com/content/9/1/265
Assay of TGF-β2
The Quantikine Human TGF-β2 ELISA kit used in the
present study is designed to measure activated TGF-β2
in serum and plasma. A monoclonal antibody specific
for TGF-β2 has been pre-coated onto a microplate. A
total of 100 μl standards and samples were pipetted to
each well and incubated for two hours at room
temperature. After washing away any unbound sub-
stances, 200μl of HRP-linked polyclonal antibody spe-
cific for TGF-β2 is added to the wells. Following a wash
to remove any unbound antibody-enzyme reagent, a
200 μl substrate solution is added to the wells and color
develops in proportion to the amount of TGF-β2 bound
in the initial step. The color development is stopped
using 50 μl stop solution and the intensity of the color
was measured within 30 minutes at 540nm. The mini-
mum detectable level of TGF-β2is less than 7.0 pg/ml.
Assay of Caspase7 (CASP7)
CASP7 was measured using an ELISA kit, a product of
Uscn Life Science Inc., Wuhan, China, according to the
manufacturer’s instructions. The microtiter plate pro-
vided in this kit has been pre-coated with an antibody
specific to CASP7. Standards or samples are then added
to the appropriate microtiter plate wells with a
biotin-conjugated polyclonal antibody preparation spe-
cific for CASP7 and incubated for two hours at room
temperature. Next, avidin conjugated to HRP is added to
each microplate well and incubated. Then a TMB sub-
strate solution is added to each well. Only those wells
that contain CASP7, biotin-conjugated antibody and
enzyme-conjugated avidin will exhibit a change in color.
The enzyme-substrate reaction is terminated by the
addition of a sulphuric acid solution and the color
change is measured spectrophotometrically at a wave-
length of 450 nm2 nm. The concentration of CASP7 in
the samples is then determined by comparing the O.D.
of the samples to the standard curve. The minimum de-
tectable level of CASP7detected is less than 0.065 ng/ml.
Assay of IFNγ
IFNγ was measured using an ELISA kit, a product of
Thermo Scientific (Rockford, IL, USA) according to the
manufacturer’s instructions. This assay employs a quan-
titative sandwich enzyme immunoassay technique that
measures IFNγ in less than five hours. A polyclonal anti-
body specific for human IFNγ has been pre-coated onto
a 96-well microplate. IFNγ in standards and samples is
sandwiched by the immobilized antibody and biotiny-
lated polyclonal antibody specific for IFNγ, which is
recognized by a streptavidin-peroxidase conjugate. All
unbound material is then washed away and a peroxidase
enzyme substrate is added. The color development is
stopped and the intensity of the color is measured at
550 nm and subtracted from absorbance at 450 nm. The
minimum level of IFNγ detected by this product is less
than 2 pg/ml.
Statistical analysis
A SPSS (Statistical Package for the Social Sciences com-
puter program was used. Results were expressed as
mean ± S.D. and all statistical comparisons were made
by means of independent t-test with P ≤0.05 considered
as significant. ROC analysis was performed. Area under
the curve, cutoff values selected by the program together
Table 1 HSP70 (ng/ml), TGF-β (pg/ml), Caspase-7 (ng/ml)
and INFγ (ng/ml) of control and autistic groups
Parameters Groups N Mean ± S.D. P-value
HSP70 (ng/ml) Control 19 10.17 ± 2.05 0.001
Autistic 20 15.82 ± 2.21
TGF-β (pg/ml) Control 19 68.30 ± 10.35 0.001
Autistic 20 101.80 ± 8.86
Caspas-7 (ng/ml) Control 19 5.63 ± 1.07 0.001
Autistic 20 8.74 ± 1.43
INF-γ (ng/ml) Control 19 50.85 ± 5.71 0.001
Autistic 20 85.33 ± 9.06
Table 1 describes the independent T-Test between the control and autistic
groups in HSP70 (ng/ml), TGF-β (pg/ml), Caspase-7 (ng/ml) and INF-γ (ng/ml).
HSP-70 (ng/ml)
13.012.011.010.09.08.07.06.0





















Std. Dev = 2.21
Mean = 15.8
N = 20.00
Figure 1 Normal distribution for control and autistic groups in HSP-70 (ng/ml).
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with degree of specificity and sensitivity were calculated.
Moreover, the predictiveness diagrams of the four mea-
sured parameters were drawn in which the x axis repre-
sents percentile rank of the biomarker, y axis represents
the probability of identifying the disease and the hori-
zontal line is the prevalence of the disease using a Bio-
stat 16 computer program.
Results
Table 1 and Figures 1, 2, 3, 4 demonstrate the significant
increase of the four measured parameters in autistic
patients compared to healthy age- and gender-matched
control subjects. Figure 1 shows that 19/20 of the autis-
tic samples recorded a HSP-70 concentration greater
than 12 ng/ml while 16/19 of the controls show values
remarkably lower than this value. All autistic patients
recorded values greater than 80 pg/ml or 7.5 ng/ml as
the maximum concentration seen in control subjects for
TGF-β and Caspase-7, respectively (Figures 2 and 3).
Additionally, 10/20 of autistics recorded concentrations
of INF-γ greater than 85ng/ml while 15/19 of the con-
trols show values lower than 57.5 ng/ml (Figure 4).
Figure 5 demonstrate the percentage increase in the
measured parameters. It could be easily noticed that
INF-γ recorded the highest increase (67.8%) while TGF-
β2 recorded the lowest increase (49.04%). Table 2 and
Figures 6 and 7 demonstrate the ROC analysis of the
measured parameters (area under the curve, specificity
and sensitivity).
Figure 8 shows the predictiveness diagrams of the four
measured parameters in relation to the prevalence of
autism in Saudi Arabia, which was most recently
recorded as 18 per 10,000 persons [16].
Discussion
In a recent hypothesis proposed by Theoharides and
Zhang [17], an association among neuroinflammation,
mast cell activation and seizures, through secretion of
pro-inflammatory mediators and regulation of the BBB
permeability was suggested. Despite a large amount of
research, the pathogenic mechanism of autism has not
yet been clarified. Abnormal protein folding [17,18] oxi-
dative stress [19], mitochondrial dysfunction [20], and
apoptotic mechanisms [8] have all been reported as
causes of neurodegeneration in association with neu-
roinflammatory mechanisms which, by generating dele-
terious molecules, could promote the cascade of events
leading to autism. Heat shock proteins (HSPs) play a
central role in preventing protein misfolding and
80.075.070.065.060.055.050.045.0
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Figure 2 Normal distribution for control and autistic groups in TGF-β (pg/ml).
Caspas-7 (ng/ml)
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Std. Dev = 1.43
Mean = 8.74
N = 20.00
Figure 3 Normal distribution for control and autistic groups in Caspase-7 (ng/ml).
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inhibiting apoptotic activity, and represent a class of pro-
teins potentially involved in neurological disorders [10].
The significant increase in HSP70 reported in the
present study could be easily related to oxidative stress
as the most important mechanism involved in the eti-
ology of autism. In spite of the protective role of HSPs,
they are only effective when up-regulated in the right
place (that is, be cell specific), at the right time and to a
level and specificity that ensures that all the important
binding partners, namely the co-chaperones, are also
present at the appropriate levels [21]. So, even though
heat shock proteins are known to inhibit various types
of apoptosis, some studies show that heat or elevated
HSP70 also potentiates cell death following specific
stimuli. The unexpected elevation of HSP70 could be
related to the etiology of autism by considering the fact
that HSP70 initiates TNF-mediated apoptosis by binding
IκB kinase (IKK) and impairing nuclear factor-kappaB
(NF-κB) survival signaling due its inactivation after being
phosphorylated [22]. This explanation could be sup-
ported through considering the recent work of El-
Ansary et al. [8], in which they recorded a significantly
lower TNF-α in the same plasma samples used for the
current study. Moreover, a number of studies have also
shown that heat shock or elevated HSP70 suppresses
NF-κB activity[23-27].Although these studies imply the
possibility that HSP70 impairs NF-κB signaling, the
exact molecular basis of the Hsp70 and NF-κB inter-
action is still not clarified. Elevation of HSP70 reported
in the present study could be supported and related to
the heavy metal toxicity (mercury) and the inability to
adequately up-regulate metallothionein (MT) biosyn-
thesis in response to the heavy metal challenge by autis-
tic patients, which was recently recorded in the same
investigated samples (unpublished work). Cultured lym-
phocytes from autistic children when challenged with 10
μM ethyl mercury responded in a different pattern than
those of non-autistic siblings. Following the challenge,
autistic cultured lymphocytes responded by up-
regulating numerous heat shock protein transcripts, but
not MTs [28].
The remarkable increase of TGF-β2 in plasma of autis-
tic patients reported in the present study could be
related to brain injury in autism because it is well known
that this cytokine is expressed in the lesioned brain [9]
and is up-regulated in the central nervous system fol-
lowing ischemia-induced brain damage [29,30]. Al-
though TGF-β2 is often considered an anti-inflammatory
molecule, we could propose that enhanced TGF-β2 ex-
pression may play a certain role in promoting
INF-Y (ng/ml)
60.057.555.052.550.047.545.042.540.037.5
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Figure 4 Normal distribution for control and autistic groups in INF-γ (ng/ml).
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Figure 5 Percentage change of HSP-70 (ng/ml), TGF-β (pg/ml), Caspase-7 (ng/ml) and INF-γ (ng/ml) in the autistic group compared to
control.
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inflammation in brain injury associated with autism. Be-
cause TGF-β1 and TGF-β2 exhibit a combination of spe-
cific and shared roles in the regulation of inflammation,
this suggestion could find a support in the previous
work which indicates that injection of an antiserum
directed against TGF-β1 reduces inflammation in the
CNS after traumatic injury, and astroglial overproduc-
tion of TGF-β1 enhances inflammatory CNS disease in
transgenic mice [31-33]. The elevated TGF-β2 reported
in the present study is in good agreement with the previ-
ous work of Vargas et al. [2] in which they found TGF-
β1 among the neuroinflammatory cytokines elevated in
the cerebral cortex, white matter and notably in the
cerebellum of autistic patients. The recorded increase of
plasma TGF-β2 as a marker of elevated TGF-β2 in the
brain could be easily related to amyloid beta (Aβ) gener-
ation previously recorded in autistic patients [34,35].
This could be supported through considering the work
of Lesne et al. [36], in which they show that TGF-β1
added to human astrocyte cultures promotes perivascu-
lar inflammation, interactions with and increased pro-
duction of amyloid beta precursor protein (AβPP) and
subsequent Aβ generation.
Caspases as a family of cysteine proteases play central
roles in coordinating the stereotypical events that occur
during apoptosis. Because the major executioner cas-
pases, Caspase-3 and Caspase-7, exhibit the most potent
activity toward certain synthetic peptide substrates, this
has led to the widespread view that both occupy critical
roles within the cell death machinery [37]. Additionally,
Erener et al. [38] propose an apoptosis-independent
regulatory role for Caspase 7-mediated cleavage of poly
(ADP-ribose) polymerase family, member 1 (PARP1) as
a DNA repair-associated enzyme that has multiple roles
in cell death. The significant elevation of Caspase 7
reported in the present study could be easily related to
the impaired NF-κB signaling survival activity as previ-
ously attributed to HSP70 but through a different mech-
anism. Elevation of Caspase 7 again confirms the
contribution of brain cell death and proinflammation in
the etiology of autism as previously reported in our re-
cent work in 2011 [8], in which Caspase 3 as a pro-
apoptotic biomarker was significantly lower in plasma
which might indicate its increase in the brain of Saudi
autistic patients compared to age- and gender-matched
controls. Moreover, both studies are consistent with the
most recent work of Siniscalco et al. [14] in which they
prove the increase of protein levels of caspase-3, -7 and
−12 in autistic patients and suggest the possible role of
the caspase pathway in autism clinical presentation and
the use of caspases as potential diagnostic and/or thera-
peutic tools.
Immune factors, such as autoimmunity, have been
implicated in the genesis of autism [3].The increase of
IFN-γ reported in the present study may indicate anti-
genic stimulation of Th-1 cells pathogenetically linked to
autoimmunity in autism. The reported elevation of IFN-
γ could support the previous work of Molloy et al. [5]























ROC Curve      TGF-β2 (pg/ml)
Figure 6 ROC Curve of HSP-70 (ng/ml) and TGF-β (pg/ml) in the autistic group.
Table 2 ROC analysis of the measured parameters shows, area under the curves, specificity and sensitivity
Parameter Area under the curve Cutoff value Sensitivity % Specificity %
HSP-70 (ng/ml) 0.987 12.218 95.0% 84.2%
TGF-β (pg/ml) 1.000 78.649 100.0% 89.5%
Caspase-7 (ng/ml) 0.968 6.698 90.0% 89.5%
INF-γ (ng/ml) 1.000 56.558 100.0% 78.9%
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showing that PBMNC of autistic children produce re-
markably high levels of Il-12 and IFN-γ, or express
higher than normal levels of mRNA for IFN-γ [39] and
the most recent work of Tostes et al. [40] that plasma
levels of vasoactive intestinal peptide (VIP), IFN-γ and
NO were significantly higher in children with autism,
compared to the healthy subjects and that a positive
correlation between plasma levels of NO and IFN-γ
exists. Moreover, they suggested additional evidence that
higher levels of IFN-γ may be associated with increased
oxidative stress, a phenomenon greatly involved in the
etiology of autism [19]. Collectively, the present study
together with the previously mentioned studies confirm






































































Figure 8 Predictivness diagrams of the four studied parameters in relation to autism prevalence in Saudi Arabia.
























Figure 7 ROC Curve of Caspase-7 (ng/ml) and INF-γ (ng/ml) in the autistic group.
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autistic children and that would also be consistent with
an autoimmune pathology, simply because IFN-γ is
among the cytokines well known for inducing auto-
immune diseases. Based on the fact that the predictive-
ness curve is better if it is farther away from the
prevalence line and useless if it is close to the prevalence
line, the predictiveness curves of the four measured
parameters (Figure 8a-d), varies significantly from the
baseline risk depending on whether HSP70, TGF-β2,Cas-
pase 7 and IFNγ concentrations were low or very high.
This shows their usefulness as predictive biomarkers.
This could be supported by the high sensitivity and spe-
cificity recorded through ROC analysis (Figures 6 and 7).
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